Cipla And mAbxience Partner For Essential Biosimilars In South Africa
Partners Will Focus On Oncology And Respiratory-Related Biosimilars
Cipla has partnered with mAbxience to supply oncology and respiratory-related biosimilars on the WHO model list of essential medicines to South Africa.
You may also be interested in...
Amneal has struck a deal with mAbxience to gain US rights to two denosumab biosimilars referencing the Prolia and Xgeva brands that have annual US sales in excess of $4bn.
Alvotech, fresh from a round of financing, has grand plans to market its biosimilar candidates across the globe. A new partnership just signed with South Africa-based Cipla Medpro will cover five candidates, including two in oncology.
Kelix bio has announced two deals to expand its presence in Africa. The company is set to acquire 14 oncology injectable products from Germany-based Vitane. Furthermore, Kelix has acquired Pharmaceutical Institute, a pharmaceutical company established in Rabat, to enter Morocco. The pan-African company has also invested in Malta.